Clinical Trials Logo

Hypersensitivity clinical trials

View clinical trials related to Hypersensitivity.

Filter by:

NCT ID: NCT05644795 Recruiting - Sjogren's Syndrome Clinical Trials

Wheat-free Diet in the Treatment of Sjogren's Syndrome

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Recent data show that some foods can increase intestinal mucosa permeability and immune activation of subjects with gastrointestinal (GI) symptoms. Wheat seems the most frequent food which activates this inflammatory response and can cause both GI and extra-intestinal symptoms. Patients suffering from wheat-related troubles, in absence of celiac disease diagnosis, can suffer from non-celiac wheat sensitivity (NCWS) and our previous studies showed that about 25% of them are also affected by autoimmune diseases (AD). A gluten-free diet (GFD) can influence inflammatory pattern of AD, including Sjogren's syndrome (SS). Thus, the investigators would enquire if SS patients may also suffer from NCWS and how a wheat-free diet (WFD) modifies their clinical features, and inflammatory and cytokine pattern. The investigators will also assess how wheat reintroduction, by an open challenge, modifies their clinical parameters, intestinal permeability, and both local and systemic inflammatory response.

NCT ID: NCT05644782 Recruiting - Psoriasis Clinical Trials

Dietary Approach to Mild-to-moderate Psoriasis

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Psoriasis is a systemic chronic inflammatory immune-mediated disease whose etiopathogenetic mechanisms involve genetic predisposition, and immunological and environmental factors. Its prevalence is about 3% in adults, and it is characterized by well-demarcated, erythematous plaques, covered by silvery-white scales, in elbows, knees, trunk, and scalp. However, psoriasis is far from being considered just a dermatologic condition because the cytokine's cascade, which lays behind its inflammatory and immune-mediated pathogenesis, can determine multiple systemic manifestations. In addition, several patients with psoriasis often complains of gastrointestinal (GI) symptoms. Therefore, authors focused their attention over the gut-skin axis and its possible pathogenetic and immunoregulatory role in psoriasis (i.e., altered gut barrier, increased blood concentration of gut microbiota-derived metabolites, systemic inflammation). In this context, several dietetic approaches (e.g., Mediterranean, low calories, protein-restricted, vegetarian diets, and gluten-free diet, GFD) have shown a certain efficacy in improve psoriasis cutaneous and systemic manifestations. In recent years, the existence of a wheat-related disorder in patients who do not suffer from CD or wheat allergy (WA) has been definitively ascertained and defined as Non-Celiac Wheat Sensitivity (NCWS). Its prevalence in the general population is unknown, but self-reported NCWS is around 10%. This condition is characterized by both GI and extraintestinal symptoms, which are triggered by wheat ingestion. In these patients, wheat ingestion might lead to alteration in intestinal permeability and gut microbiota and to systemic immune activation and inflammation. Based on the evidence of gut involvement in the pathogenesis and clinical manifestation of psoriasis, as well as on the ability of gluten/wheat to increase intestinal permeability, it could be hypothesized that gluten/wheat may represents one of the pathogenetic environmental factors of psoriasis and that its intake may be able to worsen symptoms in affected patients. The investigators hypothesize that a wheat-free diet (WFD) can reduce the inflammatory state and ameliorate the clinical symptoms in psoriasis patients. The successive clinical and immunologic reaction to the re-exposure to wheat ingestion, performed by an open challenge, will be also evaluated to confirm a wheat-dependent mechanism and to understand the underlining physiopathology.

NCT ID: NCT05634694 Recruiting - Cholangiocarcinoma Clinical Trials

Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients

Start date: November 30, 2022
Phase:
Study type: Observational

This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the consistency and accuracy of patient-derived organoid model of cholangiocarcinoma to predict the clinical chemotherapeutic efficacy, as well as the possibility of guiding the adjuvant chemotherapy.

NCT ID: NCT05634473 Not yet recruiting - Asthma Clinical Trials

A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test

Start date: December 2022
Phase: N/A
Study type: Interventional

A multicenter, open-label study to evaluate the sensitivity and specificity of inhaled methacholine in bronchial provocation test

NCT ID: NCT05630027 Completed - Alopecia Clinical Trials

A Scalp Lotion Toimprove Sensitive Scalp Syndrome

Start date: January 2, 2019
Phase:
Study type: Observational

Overall, 100 Caucasian subjects participated in this 6-weeks lasting study, AC5+ was applied daily. All subjects had clinically confirmed mild to moderate alopecia and self-declared sensitive scalp. Instrumental assessments included Trans Epidermal Water Loss (TEWL), inflammation markers, clinical assessments included the severity of erythema, inflammation and greasiness. Subjective/Self assessments comprised the intensity of the scalp itch/pruritus and the evaluation of their head hair status (volume, abundance, strength). Same assessments were provided by the investigators.

NCT ID: NCT05626387 Recruiting - Clinical trials for Hypersensitivity Pneumonitis

An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis

MYCOHYPE
Start date: November 23, 2022
Phase: Phase 4
Study type: Interventional

To our knowledge, there is no randomized controlled trial assessing the efficacy of mycophenolate mofetil (MMF) in the treatment of HP. We aim to perform a randomized study to assess the efficacy and safety of a regimen consisting of MMF and prednisolone against a regimen consisting of prednisolone alone for treating fibrotic HP. We hypothesize that the treatment of patients with fibrotic HP with MMF and prednisolone will be more effective and safer than treatment with prednisolone alone.

NCT ID: NCT05625672 Completed - Nurse's Role Clinical Trials

EFFICIENCY OF HEMOVIGILANCE MODULE TRAININGS GIVEN TO NURSES

Start date: April 25, 2022
Phase: N/A
Study type: Interventional

The aim of the present study is to determine the effectiveness of hemovigilance module training given to nurses.

NCT ID: NCT05623826 Completed - Stress Clinical Trials

Feasibility and Efficacy of a Digital Training Intervention to Increase Reward Sensitivity- Imager

IMAGER
Start date: September 27, 2020
Phase: N/A
Study type: Interventional

Development and feasibility test of an Ecological Momentary Intervention (EMI) - Imager, to promote and improve stress resilience, specifically to increase reward sensitivity.

NCT ID: NCT05623761 Completed - Gingivitis Clinical Trials

Toothpastes With Thermal Water for Oral Health

Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

The aim of the study is to compare the effect of toothpastes containing thermal water of Castera-Verduzan with 1450 ppm fluoride and without fluorinated derivatives on oral hygiene, gingivitis, and dentin hypersensitivity in young adults.

NCT ID: NCT05621317 Recruiting - Clinical trials for Immune System Diseases

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Start date: February 9, 2023
Phase: Phase 2
Study type: Interventional

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.